WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Previous studies have suggested a tendency of antifolate drugs to be associated with higher rates of neural tube defects. WHAT THIS STUDY ADDS: * This study makes use of the data on abortuses, which is missed in many other studies. In this case, the abortion data were critical. * The study documents that clinicians should avoid, as much as possible, the use of folic acid antagonists during the first trimester of pregnancy, when embryogenesis takes place. AIM: To investigate the safety of folic acid antagonists during the first trimester of pregnancy in a large cohort. METHODS: Computerized databases for medications dispensed from 1998 to 2007 to women registered in 'Clalit' HMO, Israel southern district, was linked with maternal and infant hospitalization records, and to therapeutics abortions data. The risk for adverse pregnancy outcomes of folic acid antagonists exposure was assessed by adjusting for known confounders. RESULTS: Eighty-four thousand, eight hundred and twenty-three infants were born and 998 therapeutic abortions took place; 571 fetuses and infants were exposed to one or more folic acid antagonists in the first trimester of pregnancy. Exposure was associated with an overall increased risk of congenital malformations [odds ratio (OR) 2.43, 95% confidence interval (CI) 1.92, 3.08], due mainly to increased risk for neural tube (adjusted OR 6.5, 95% CI 4.34, 9.15) and cardiovascular defects (OR 1.76, CI 1.05, 2.95). CONCLUSION: First-trimester exposure to folic acid antagonists is associated with increased risk of congenital malformations.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Previous studies have suggested a tendency of antifolate drugs to be associated with higher rates of neural tube defects. WHAT THIS STUDY ADDS: * This study makes use of the data on abortuses, which is missed in many other studies. In this case, the abortion data were critical. * The study documents that clinicians should avoid, as much as possible, the use of folic acid antagonists during the first trimester of pregnancy, when embryogenesis takes place. AIM: To investigate the safety of folic acid antagonists during the first trimester of pregnancy in a large cohort. METHODS: Computerized databases for medications dispensed from 1998 to 2007 to women registered in 'Clalit' HMO, Israel southern district, was linked with maternal and infant hospitalization records, and to therapeutics abortions data. The risk for adverse pregnancy outcomes of folic acid antagonists exposure was assessed by adjusting for known confounders. RESULTS: Eighty-four thousand, eight hundred and twenty-three infants were born and 998 therapeutic abortions took place; 571 fetuses and infants were exposed to one or more folic acid antagonists in the first trimester of pregnancy. Exposure was associated with an overall increased risk of congenital malformations [odds ratio (OR) 2.43, 95% confidence interval (CI) 1.92, 3.08], due mainly to increased risk for neural tube (adjusted OR 6.5, 95% CI 4.34, 9.15) and cardiovascular defects (OR 1.76, CI 1.05, 2.95). CONCLUSION: First-trimester exposure to folic acid antagonists is associated with increased risk of congenital malformations.
Authors: Sonja A Rasmussen; Richard S Olney; Lewis B Holmes; Angela E Lin; Kim M Keppler-Noreuil; Cynthia A Moore Journal: Birth Defects Res A Clin Mol Teratol Date: 2003-03
Authors: R W Smithells; S Sheppard; C J Schorah; M J Seller; N C Nevin; R Harris; A P Read; D W Fielding Journal: Lancet Date: 1980-02-16 Impact factor: 79.321
Authors: Jennifer A Makelarski; Paul A Romitti; Carissa M Rocheleau; Trudy L Burns; Patricia A Stewart; Martha A Waters; Christina C Lawson; Erin M Bell; Shao Lin; Gary M Shaw; Richard S Olney Journal: Birth Defects Res A Clin Mol Teratol Date: 2014-08-15
Authors: Craig Hansen; Susan E Andrade; Heather Freiman; Sascha Dublin; Katie Haffenreffer; William O Cooper; T Craig Cheetham; Sengwee Toh; De-Kun Li; Marsha A Raebel; Jennifer L Kuntz; Nancy Perrin; A Gabriela Rosales; Shelley Carter; Pamala A Pawloski; Elizabeth M Maloney; David J Graham; Leyla Sahin; Pamela E Scott; John Yap; Robert Davis Journal: Pharmacoepidemiol Drug Saf Date: 2015-11-24 Impact factor: 2.890